| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Carroll Jill serves as a Director at AVLN and has filed Form 4s across 2 companies. Across recent SEC filings that breaks down to 3 buys and 6 sells. Those positions are worth an estimated $39.4M at current prices.
Historically, Carroll Jill's trades have earned a middling insider score of 56/100 across 6 rated trades. Over a 12-month horizon, 33.3% of those trades were profitable, with an average 12-month return of -5.3%.
The biggest single holding is AVLN (~$39.4M) as Director. Net of sales, the recent Form 4 record there shows accumulation of 277,778 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | AVLN Avalyn Pharma Inc. Common Stock | Director | Buy | 277,778 | $18.00 | $5,000,004.00 | +14.6% | - | - | |
| Mar 21, 2024 | ACLX Arcellx, Inc. | Director | Sell | 504,263 | $70.55 | $35,575,754.65 | -25.4% | -24.2% | -3.8% | |
| Dec 14, 2023 | ACLX Arcellx, Inc. | Director | Sell | 504,263 | $49.13 | $24,774,441.19 | -20.3% | +37.5% | +63.4% | |
| Jun 1, 2023 | ACLX Arcellx, Inc. | Director | Sell | 340,720 | $41.71 | $14,212,622.60 | -12.0% | -19.9% | +17.3% | |
| May 11, 2023 | ACLX Arcellx, Inc. | Director | Sell | 638,417 | $45.01 | $28,736,222.75 | -18.4% | -22.5% | +11.6% | |
| Feb 8, 2022 | ACLX Arcellx, Inc. | Director | Buy | 1,666,667 | $15.00 | $25,000,005.00 | +454.7% | -52.0% | +75.2% |